ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.

Zhejiang Tianyu Pharmaceutical Co., Ltd.

300702

CNE1000034X1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
17.83 ^CNY	-0.34%		-3.67%	-17.87%

31/05	Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024	CI
06/05	China Approves Tianyu Pharma's Heart Medication	MT

Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024

May 01, 2024 at 01:02 am IST

Zhejiang Tianyu Pharmaceutical Co., Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 0.50000000. Record date: 05 June 2024; Ex-date: 06 June 2024; Payment date: 06 June 2024.

Latest news about Zhejiang Tianyu Pharmaceutical Co., Ltd.

Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Dividend Implementation for 2023, Payable on 06 June 2024	01/06	CI
China Approves Tianyu Pharma's Heart Medication	06/05	MT
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024.	30/04	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 24, 2024, has closed with 1,646,420 shares, representing 0.48% for CNY 27.79 million.	30/04	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Profit Distribution Proposal for 2023	27/04	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 24, 2024.	03/04	CI
Zhaoxin Liaowang No. 1 Private Securities Investment Fund managed by Jiangsu Zhaoxin Private Fund Management Co., Ltd. entered into a share transfer agreement to acquire 6.19% stake in Zhejiang Tianyu Pharmaceutical Co., Ltd. from Ganzhou Zhenhan Venture Capital Co., Ltd. for CNY 310 million.	20/03	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	24/01	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	24/01	CI
Tianyu Pharmaceutical Unit Passes US FDA's On-Site Inspection	22/11	MT
Tianyu Pharma Unit Passes US FDA On-Site Inspection	20/11	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/23/26	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Zhuhai Rundu Pharma Gets Supplementary Application Approval For Hypertension Drug	26/23/26	MT
Raw Drug Material of Tianyu Pharma's Unit Passes Regulatory Evaluation	16/23/16	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1.4 billion in funding	16/23/16	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd. Announces Management Changes	24/23/24	CI
Tianyu Pharmaceutical Unit Gets Approval to Market Hypertension Drug in China	09/23/09	MT
Zhejiang Tianyu Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	26/23/26	CI
Zhejiang Tianyu Pharma Unit Gets Marketing Approval For Losartan Potassium Tablets	21/23/21	MT
Tranche Update on Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 30, 2022.	15/22/15	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 30, 2022, has expired with 2,403,643 shares, representing 0.69% for CNY 58 million.	15/22/15	CI
Zhejiang Tianyu Pharmaceutical Co., Ltd.(SZSE:300702) dropped from Shenzhen Stock Exchange Component A Share Index	09/22/09	CI

Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.

Duration

Period

Chart Zhejiang Tianyu Pharmaceutical Co., Ltd.

More charts

Company Profile

Zhejiang Tianyu Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of chemical raw materials. The Company operates three segments. The Pharmaceutical Intermediates segment include hypertension drugs raw materials, anti-asthma drugs raw materials and anticoagulant drugs raw materials. The Active Pharmaceutical Ingredients (API) segment is engaged in production of high blood pressure drug intermediates, anti-asthma drug intermediates and antiviral drug intermediates. The Company also operates Other segment. The Company sells its products to both domestic and international markets, including Europe, the United States, Japan, South Korea and so on.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zhejiang Tianyu Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.83 CNY

Average target price

22.6 CNY

Spread / Average Target

+26.75%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG TIANYU PHARMACEUTICAL CO., LTD.	-17.87%	844M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.50%	43.77B
OTSUKA HOLDINGS CO., LTD.	+28.11%	22.83B
SANDOZ GROUP AG	+20.25%	15.56B
CIPLA LIMITED	+19.27%	14.34B
ZYDUS LIFESCIENCES LIMITED	+56.10%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.24%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B

Generic Pharmaceuticals